Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
INmune Bio Inc. - Common stock
(NQ:
INMB
)
1.540
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about INmune Bio Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
Next >
INmune Bio: Q4 Earnings Insights
↗
March 28, 2024
Via
Benzinga
Earnings Scheduled For March 28, 2024
↗
March 28, 2024
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
Via
Benzinga
A Preview Of INmune Bio's Earnings
↗
March 27, 2024
Via
Benzinga
Earnings Outlook For INmune Bio
↗
August 04, 2023
Via
Benzinga
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
March 26, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
March 13, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
March 05, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 12, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
February 06, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
January 30, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
Why Is Elevai Labs (ELAB) Stock Up Today?
↗
January 16, 2024
Elevai Labs is soaring on an intriguing licensing agreement with INmune Bio, but the narrative presents a mixed bag for ELAB stock.
Via
InvestorPlace
Why Elevai Labs Stock Is Trading Higher
↗
January 16, 2024
Elevai Labs, Inc. (NASDAQ:ELAB) shares are trading higher Tuesday after the company announced it signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune...
Via
Benzinga
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
January 16, 2024
ELEVAI Labs to commercialize use of proprietary technology designed to produce high-quality, cGMP grade mesenchymal stromal cells at lower-cost
From
Elevai Labs Inc.
Via
GlobeNewswire
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
January 02, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
↗
December 19, 2023
It's time to dive into the biggest pre-market stock movers as we check out all of the most recent news for Tuesday morning!
Via
InvestorPlace
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
December 18, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
November 29, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
November 27, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
↗
November 17, 2023
Biotech companies are edging closer to finding the answers behind Alzheimer's disease.
Via
Investor's Business Daily
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
November 15, 2023
The Company received regulatory approval to extend its Phase II trial of XPro™ in individuals with early Alzheimer’s disease in Poland, with additional European Union (EU) countries expected to open...
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority
October 31, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα
October 30, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 17, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1
October 16, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference
September 07, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’s Disease
September 05, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference
August 01, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7
July 31, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.
July 12, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Announces New Findings to Be Presented at Annual AAIC
July 11, 2023
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
